ADAPTIVE BIOTECHNOLOGIES CORPORATION Number of Reportable Segments
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Number of Reportable Segments of 2 Segment for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-02-26
- ADAPTIVE BIOTECHNOLOGIES CORPORATION number of reportable segments for the quarter ending 2024-03-31 was 2.00 Segment.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION number of reportable segments for fiscal 2025 was 2.00 Segment, a 0.00% change from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION number of reportable segments for fiscal 2024 was 2.00 Segment, a 100.00% increase from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION number of reportable segments for fiscal 2023 was 1.00 Segment, a 0.00% change from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION number of reportable segments for fiscal 2022 was 1.00 Segment, a 0.00% change from fiscal 2021.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2025-12-31 | 2.00 Segment 10-K · filed 2026-02-26 | |||
| 2024-12-31 | 2.00 Segment 10-K · filed 2025-03-03 | |||
| 2024-09-30 | 2.00 Segment 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | 2.00 Segment 10-Q · filed 2024-08-01 | |||
| 2024-03-31 | 2.00 Segment 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | 1.00 Segment 10-K · filed 2024-02-29 | |||
| 2022-12-31 | 1.00 Segment 10-K · filed 2023-02-14 | |||
| 2021-12-31 | 1.00 Segment 10-K · filed 2022-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |